<DOC>
	<DOC>NCT02594501</DOC>
	<brief_summary>The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 6-month DAPT.</brief_summary>
	<brief_title>Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy</brief_title>
	<detailed_description />
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<criteria>Ischemic symptoms (stable or unstable angina) or evidence of myocardial ischemia in the presence of â‰¥ 50% de novo stenosis located in native coronary vessels Patient receiving or with an indication for new treatment with longterm oral anticoagulation with a coumadin derivatives or nonvitamin K oral anticoagulants. Written, informed consent Cardiogenic shock Target lesion located in left main trunk Bifurcation interventions with a planned 2stent strategy Vessel size too small for implantation of a 2.5 mm stent by visual estimation Patient requiring staging PCI procedure within 6 months after the index procedure Patients requiring DAPT for more than 2 weeks after the index procedure Contraindications or allergy to cobalt, chromium, platinum, polyzeneF, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months Relevant hematologic deviations: platelet count &lt;100x10^9 cells/L or &gt;600x10^9 cells/L Active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol noncompliance Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives Patient's inability to fully cooperate with the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>